Expert Interviews

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

Adult T-cell lymphoma and leukemia may warrant up-front allogeneic transplant, according to Mary Jo Lechowicz, MD.

In this segment, Elizabeth Bohannon discusses practical strategies that helped her manage treatment-related challenges and maintain quality of life during her relapsed/refractory multiple myeloma journey.

In this segment, Isabel Curtin, LCSW, discusses how psychosocial support can help patients cope with treatment-related adverse effects that may not be visible to others but can still significantly affect emotional well-being, relationships, and daily life.

In the closing remarks, Dr. Shambavi Richard reflects on the key themes that emerged throughout the discussion on the evolving role of BCMA-directed therapies in relapsed/refractory multiple myeloma (R/R MM).

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.

Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.

Azacitidine/venetoclax improving EFS over chemotherapy in fit patients with AML is an “important outcome,” according to Amir T. Fathi, MD.

The faculty step back to compare trial data with real-world evidence before reviewing a phase 3b feasibility study.

The first clinical scenario focuses on a 66-year-old patient with multiple myeloma who develops biochemical progression during lenalidomide maintenance after frontline therapy and autologous stem cell transplantation.

The discussion expands to investigational CELMoDs in multiple myeloma, focusing on cemsidomide and the ongoing MOMENTUM trial.

The risk of infections with epcoritamab plus R2 appeared to level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.

At SOHO 2026, David Sallman, MD, explained why ofirnoflast produced responses across MDS subtypes, including in a patient with TP53-mutant disease.

Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.

Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.

DISC-3405 may serve as an adjunctive therapy, not a replacement, for hydroxyurea or interferon, according to Naseema Gangat, MBBS.

DISC-0974 may have utility as monotherapy or in combination with other JAK inhibitors, according to Naseema Gangat, MBBS.

Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.

Josef Vymazal, MD, discussed a randomized study showing delayed double-dose gadopiclenol significantly improved detection of small brain metastases compared with standard imaging.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.

Clinicians weigh alpelisib’s hyperglycemia, rash, diarrhea and increasingly favor capivasertib for lower glucose risk with close monitoring.

Explore evolving options for biomarker-negative metastatic breast cancer, from CDK4/6 rechallenge to gadeptolizumab and PAM-pathway targeted therapy.

Josef Vymazal, MD, explained why high-relaxivity contrast agents are critical for detecting small brain metastases, despite weaker agents remaining suitable for other indications.

The faculty discuss treatment sequencing for a patient with relapsed/refractory multiple myeloma (R/R MM) who has experienced disease progression following prior BCMA-directed therapy.

In this segment, Elizabeth Bohannon shares practical strategies she used to manage treatment-related toxicities during her relapsed/refractory multiple myeloma journey, particularly dry mouth, oral health changes, nail changes, and skin toxicity associated with talquetamab.

Lisa Cassileth, MD, FACS, spoke about how mastectomy flap necrosis can delay systemic therapy and radiation, and what teams can do.

The faculty discuss treatment selection for a fit patient with relapsed/refractory multiple myeloma (R/R MM) who is eligible for both CAR-T cell therapy and BCMA bispecific antibodies and has access to a certified CAR-T treatment center.

In this segment, Elizabeth Bohannon discusses the treatment-related adverse effects that had the greatest impact on her daily life throughout her relapsed/refractory multiple myeloma journey.